Similar Papers

Paper Title
Journal
Date
Author
Conditionally Activated IL-12 or IFNα Indukine™ Molecules Inhibit Syngeneic Lymphoma Tumor Growth in Mice, Induce Anti-Tumor Immune Responses and Are Tolerated in Non-Human Primates
Philipp Steiner ... William Winston
Blood | VOL. 138
Philipp Steiner, et. al.Philipp Steiner ... William Winston
05 Nov 2021
Abstract 2055: WTX-330 is a conditionally activated IL-12 prodrug that fundamentally reprograms tumor infiltrating CD8+ T cells and drives tumor regression
Christopher J Nirschl ... Andres Salmeron
Cancer Research | VOL. 82
Christopher J Nirschl, et. al.Christopher J Nirschl ... Andres Salmeron
15 Jun 2022
Abstract 1716: WTX-330, a conditionally activated IL-12 INDUKINE, releases IL-12 selectively in the tumor microenvironment to activate anti-tumor immune responses and induce regressions in mouse tumor models
Philipp Steiner ... Nesreen Ismail
Cancer Research | VOL. 81
Philipp Steiner, et. al.Philipp Steiner ... Nesreen Ismail
01 Jul 2021
Abstract 4074: Discovery of WTX-518, an IL-18 pro-drug that is conditionally activated within the tumor microenvironment and induces regressions in mouse tumor models
Kristin R Morris ... Heather Brodkin
Cancer Research | VOL. 84
Kristin R Morris, et. al.Kristin R Morris ... Heather Brodkin
22 Mar 2024
View more papers

More From: Journal for ImmunoTherapy of Cancer

Paper Title
Journal
Date
Author
Real-world outcomes with tisagenlecleucel in aggressive B-cell lymphoma: subgroup analyses from the CIBMTR registry
Daniel J Landsburg ... Cameron J Turtle
Journal for ImmunoTherapy of Cancer | VOL. 13
Daniel J Landsburg, et. al.Daniel J Landsburg ... Cameron J Turtle
09 Feb 2025
Phase I study of efineptakin alfa (NT-I7) for the treatment of Kaposi sarcoma
Ramya Ramaswami ... Chia-Ching Jackie Wang
Journal for ImmunoTherapy of Cancer | VOL. 13
Ramya Ramaswami, et. al.Ramya Ramaswami ... Chia-Ching Jackie Wang
06 Feb 2025
Complete metabolic response as early predictor of long-term efficacy after adoptive T cell therapy using tumor-infiltrating lymphocytes
Troels Holz Borch ... Inge Marie Svane
Journal for ImmunoTherapy of Cancer | VOL. 13
Troels Holz Borch, et. al.Troels Holz Borch ... Inge Marie Svane
06 Feb 2025
Pembrolizumab hybrid dosing is non-inferior to flat dosing in advanced non-small cell lung cancer: a real-world, retrospective bicenter cohort study
Michiel M Smeenk ... Willemijn S M E Theelen
Journal for ImmunoTherapy of Cancer | VOL. 13
Michiel M Smeenk, et. al.Michiel M Smeenk ... Willemijn S M E Theelen
06 Feb 2025
View more papers

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.